6 April 2021 - How long will we have to wait for version 2?

The agenda for the July 2021 PBAC meeting was published on the PBS website on 31 March 2021. We have analysed the agenda extensively; all submissions have been coded and entered in the MAESTrO Database. Users of the PBAC version can now undertake their own interrogations and analyses of the agenda for the next scheduled meeting of the PBAC.

Multiple versions of the agenda have been published (without notification) for previous meetings; the final version for the March 2021 meeting was labelled version 6.

Notwithstanding the fact that the agenda will be updated in week 8 to include early pathway resubmissions, and items for review under the process for reviewing positive PBS listing recommendations not accepted by applicants, we have found two reasons why the current agenda (version 1) need to be updated sooner. Version 1 of the agenda notes submissions from:

• Antengene for the new medicine selexinor (Xpovio) 200 mg tablets for the treatment of certain patients with multiple myeloma and non-Hodgkin's lymphoma - they are in fact 20 mg tablets
• Pfizer for a new formulation of etanercept (Enbrel) (50 mg/mL solution in pre-filled cartridges) for the treatment of patients with multiple diseases/conditions including non-radiographic axial spondyloarthritis. The PBAC is yet to recommended the PBS listing of etanercept for patients with non-radiographic axial spondyloarthritis (to date, two rejections).

We will monitor the PBS website for agenda updates and revisions. 

Read PBAC agenda